You are here

Press Release Archive

 
- Pfizer Reports Second-Quarter 2017 Results

Please find Pfizer’s press release and associated financial tables at the following hyperlink: Pfizer Reports Second-Quarter 2017 Results

 
- EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business...

 
- Merck and Pfizer Collaborate with Corning

Merck, Pfizer, and Corning Incorporated, today announced collaborations that have enabled the modernization of pharmaceutical packaging...

 
- BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin)...

 
- Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri

Today Pfizer Inc., (NYSE:PFE) one of the world’s premier biopharmaceutical companies, broke ground . . . 

 
- Pfizer Declares 32-Cent Third-Quarter 2017 Dividend

The board of directors of Pfizer Inc. today declared a 32-cent third-quarter 2017 dividend . . .

 
- Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805,  an investigational . . .

 
- Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority . . .

 
- Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing . . . 

 
- Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey

Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the . . . 

 
- Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the . . .

 
- Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies...

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen . . . 

 
- Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration . . . 

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.